[1]熊峰.梗阻性肥厚型心肌病治疗方法的现状与进展[J].心血管病学进展,2019,(6):889-893.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
　XIONG Feng.Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):889-893.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.013]
点击复制

梗阻性肥厚型心肌病治疗方法的现状与进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年6期
页码:
889-893
栏目:
综述
出版日期:
2019-09-25

文章信息/Info

Title:
Current Status and Progress of Treatment of Hypertrophy Obstructive Cardiomyopathy
作者:
熊峰
(西南交通大学附属医院 成都市第三人民医院心内科 成都市心血管病研究所,四川 成都 610031)
Author(s):
XIONG Feng
(The Affiliated Hospital of Southwest Jiaotong University,The Third Peoples Hospital of Chengdu,Chengdu Institute of Cardiovascular Diseases,Chengdu 610031,Sichuan,China)
关键词:
梗阻性肥厚型心肌病; 室间隔心肌切除术; 经皮室间隔化学消融术; 射频导管消融术
Keywords:
Hypertrophic obstructive cardiomyopathy; Ventricular septal myectomy; Percutaneous transluminal spetal myocardial ablation; Radiofrequency catheter ablation
DOI:
10.16806/j.cnki.issn.1004-3934.2019.06.013
摘要:
梗阻性肥厚型心肌病是一种以室间隔非对称性肥厚、二尖瓣前叶收缩期前向运动征、左室流出道梗阻和不同程度的二尖瓣反流为主要特征的常染色体显性遗传性疾病。目前该病可通过药物、外科手术、经皮室间隔化学消融术等方式治疗, 从而改善患者的临床症状，减少并发症及预防心源性猝死。现就梗阻性肥厚型心肌病治疗方法的现状与进展做一综述。
Abstract:
Hypertrophic obstructive cardiomyopathy is an autosomal dominant genetic disease characterized by ventricular septal asymmetry hypertrophy,systolic anterior motion,left ventricular outflow tract gradient, and varying degrees of mitral regurgitation. At present, the disease can be treated by drugs, surgery, percutaneous transluminal spetal myocardial ablation, etc, which greatly improves the clinical symptoms of patients, r educe complications and prevents sudden cardiac death. The current status and progress of treatment for hypertrophic obstructive cardiomyopathy are reviewed in this article.

参考文献/References:

[1].Members AF,Elliott PM,Anastasakis A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]. Eur Heart J,2015,68(1):63-63.
[2].Marian AJ,Braunwald E.Hypertrophic cardiomyopathy:genetics,pathogenesis,clinical manifestations, diagnosis, and therapy[J]. Circ Res,2017,121(7):749.
[3].Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121(3):445-456.
[4].Heitner SB,Fischer KL. Lifestyle modification and medical management of hypertrophic cardiomyopathy[J]. Cardiol Clin,2019,37(1):45-54.
[5].Saberi S,Wheeler M,Bragggresham J,et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy:a randomized clinical trial[J]. JAMA,2017,317(13):1349-1357.
[6].Gombar S,Moneghetti KJ,Callahan A,et al. Beta-blockers inferior to calcium channel blockers in hypertrophic cardiomyopathy[J]. Circulation,2017,136(suppl 1):A21307.
[7].Marian AJ,Tan Y,Liu L,et al. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy(HALT-HCM):A Randomized, Placebo-Controlled, Double-Blind Pilot Study[J]. Circ Res,2018,122(8):1109-1118.
[8].Zablocki JA,Elzein E,Li X,et al. Discovery of dihydrobenzoxazepinone (GS-6615) late sodium current inhibitor(Late INai), a phaseⅡagent with demonstrated preclinical anti-ischemic and antiarrhythmic properties[J]. J Med Chem,2016,59(19):9005-9017.
[9].Smedira NG,Lytle BW,Lever HM,et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy[J]. Ann Thorac Surg,2008,85(1):127-133.
[10].Desai MY,Bhonsale A,Smedira NG,et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction[J]. Circulation,2013,128(3):209-216.
[11].Swistel DG,Balaram SK. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the “RPR” repair:resection, plication, and release[J]. Prog Cardiovasc Dis,2012,54(6):498-502.
[12].李海清,周任,姚皓弋,等. RPR技术治疗复杂肥厚型梗阻性心肌病[J]. 上海交通大学学报（医学版）,2017,37(3):348-351.
[13].Sakaguchi T,Totsugawa T,Tamura K,et al. Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy[J]. Gen Thorac Cardiovasc Surg, 2018,66(6):321-326.
[14].Dustin H,Anita N,Schaff HV. Surgical treatment for hypertrophic cardiomyopathy:a historical perspective[J]. Ann Cardiothorac Surg,2017,6(4):318-328.
[15].Holst KA,Hanson KT,Ommen SR,et al. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery[J]. Mayo Clin Proc,2019,94(1):66-73.
[16].Jensen MK, Prinz C, Horstkotte D, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy:low incidence of sudden cardiac death and reduced risk profile[J]. Heart,2013,99(14):1012-1017.
[17].Agarwal S,Tuzcu EM,Desai MY,et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,55(8):823-834.
[18].Poon SS,Field M,Gupta D,et al. Surgical septal myectomy or alcohol septal ablation:which approach offers better outcomes for patients with hypertrophic obstructive cardiomyopathy? [J].Interact Cardiovasc Thorac Surg,2017,24(6):951-961.
[19].邓丹,孟璟,曲小龙,等.室间隔化学消融术治疗肥厚型梗阻性心肌病的临床疗效分析[J]. 第三军医大学学报, 2017,39(16):1673-1678.
[20].Meng J,Qu X,Huang H,et al. Intracoronary electrocardiogram during alcohol septal ablation for hypertrophic obstructive cardiomyopathy predicts myocardial injury size[J]. Clin Exp Pharmacol Physiol,2016,43(1):75-80.
[21].Yanagiuchi T,Tada N,Haga Y,et al. Utility of preprocedural multidetector computed tomography in alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J].Cardiovasc Interv Ther,2019,Feb 6. DOI: 10.1007/s12928-019-00574-0[Epub ahead of print].
[22].Osman M,Kheiri B,Osman K,et al. Septal alcohol ablation versus myectomy for symptomatic hypertrophic obstructive cardiomyopathy:systematic review and meta-analysis[J].Clin Cardiol,2018,42(1):190-197.
[23].Singh K,Qutub M,Carson K,et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy[J]. Catheter Cardiovasc Interv,2016,88(1):107-115.
[24].Lawrenz T,Borchert B,Leuner C,et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months’ follow-up in 19 patients[J]. J Am Coll Cardiol,2011,57(5):572-576.
[25].Riedlbauchová L,Janou?ek J,Veselka J. Ablation of hypertrophic septum using radiofrequency energy:an alternative for gradient reduction in patient with hypertrophic obstructive cardiomyopathy?[J]. J Invasive Cardiol,2013,25(6):128-132.
[26].Cooper RM,Shahzad A,Hasleton J,et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound? technology to guide ablation[J]. Europace,2016,18(1):113-120.
[27].刘丽文,左蕾,周梦垚,等. 经胸超声心动图引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病的安全性和有效性[J]. 中华心血管病杂志,2019,47(4):284-290.
[28].邹玉宝,惠汝太,宋雷. 《中国成人肥厚型心肌病诊断与治疗指南》解读[J]. 上海大学学报（自然科学版）,2018,24(1):1-8.
[29].Topilski I,Sherez J,Keren G,et al. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy＞50 years of age[J]. Am J Cardiol,2006,97(12):1769-1775.
[30].Nelson W,Ashleigh X,Richard T,et al. Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy:an updated systematic review and meta-analysis of outcomes and complications[J]. Ann Cardiothorac Surg,2017,6(4):298-306.
[31].Maksymilian P, Giulia M, Lucie C. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy[J]. Pflügers Archiv Eur J Physiol,2019,471(5): 807-815.
[32].Green EM,Wakimoto H,Anderson RL,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science,2016,351(6273):617-621.
[33].Prondzynski M,Kr?mer E,Laufer SD,et al. Evaluation of,MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes[J]. Mol Ther Nucleic Acids,2017,7:475-486.

相似文献/References:

[1]文琰 杨谋 胡宏德.梗阻性肥厚型心肌病缓解梗阻的治疗进展[J].心血管病学进展,2022,(9):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
　WEN Yan,YANG Mou,HU Hongde.Obstruction Relief Therapy in Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(6):799.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.008]
[2]徐克 孙阳 汪道文.梗阻性肥厚型心肌病的介入和外科手术治疗及进展[J].心血管病学进展,2024,(2):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
　XU Ke,SUN Yang,WANG Daowen?/html>.New Perspectives on Interventional and Surgical Treatment for?bstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(6):103.[doi:10.16806/j.cnki.issn.1004-3934.2024.02.000]
[3]姚舜禹 罗素新 黄毕.心肌肌球蛋白抑制剂在梗阻性肥厚型心肌病治疗中的研究现状[J].心血管病学进展,2024,(5):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
　YAO Shunyu,LUO Suxin,HUANG Bi.Cardiac Myosin Inhibitors in Treatment of Obstructive Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(6):397.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.004]
[4]李莎 严霜霜 熊峰.Mavacamten在肥厚型心肌病中的治疗进展[J].心血管病学进展,2024,(10):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]
　LI ShaYAN ShuangshuangXIONG Feng.Advances In the Treatment Of Mavacamten?n Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(6):907.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.009]

备注/Memo

备注/Memo:
收稿日期：2019-07-01
更新日期/Last Update: 2019-12-11